Database Registry of the Intermountain Heart Collaborative Study
The purpose of the registry is to collect and analyze clinical and laboratory data and tissue samples from patients who are diagnosed with any type of heart disease and to collect the same information and samples from healthy controls in participating Intermountain Healthcare facilities.
Coronary Artery Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Database Registry of the Intermountain Heart Collaborative Study|
- Outcome Risk [ Time Frame: 30 years ] [ Designated as safety issue: No ]To evaluate risk factors, characteristics, and treatments to cardiovascular outcomes
Biospecimen Retention: Samples With DNA
|Study Start Date:||October 1994|
|Estimated Study Completion Date:||January 2024|
|Estimated Primary Completion Date:||January 2024 (Final data collection date for primary outcome measure)|
This is a registry (database) project; there are no investigational treatments, drug or procedures associated with participation in registry activities. This project is an organized data gathering and storing (database) endeavor with specific focus on the precursors, modifiers, biological, and genetic parameters of heart disease and related medical conditions. Data collection will not immediately influence the course of treatment for any patient.Sample testing and data utilization for basic science, clinical, and epidemiologic and publication projects can be initiated using the databank.
The registry will enable researchers to determine best medical practices for predicting, preventing, and treating heart disease. The registry will: 1) develop standard methods to collect data and specimens which will be used for research to characterize patients diagnosed with heart disease as well as healthy controls and to assess differences in demographics and patient outcomes in both populations; 2) collect, process, and store patients' clinical data and tissue/blood samples; 3) analyze data collected; 4) use these resources to identify genes, genetic polymorphisms, genetic mutations, clinical methods and procedures, and/or biomarkers that predict, prevent, or treat heart disease and/or are associated correlate with lifestyle or disease outcomes; 5) publish and disseminate results.
|Contact: Joseph B Muhlestein, MDfirstname.lastname@example.org|
|United States, Utah|
|Intermountain Medical Center||Recruiting|
|Murray, Utah, United States, 84157|
|Contact: Joseph B Muhlestein, MD 801-507-4760 email@example.com|
|Sub-Investigator: Jeffrey L Anderson, MD|
|Sub-Investigator: John F Carlquist, PhD|
|Sub-Investigator: Benjamin D Horne, PhD, MPH|
|Sub-Investigator: Dale G Renlund, MD|
|Sub-Investigator: Abdallah G Kfoury, MD|
|Principal Investigator:||Joseph B Muhlestein, MD||Intermountain Healthcare, LDS Hospital|